REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) — Pulmo x Co po atio (Nasdaq: LUNG) (“Pulmo x”) a global leade i mi imally i vasive t eatme ts fo seve e lu g disease, today a ou ced that ma ageme t will pa ticipate i the followi g upcomi g i vesto co fe e ces:
Live a d a chived webcasts of the fi eside chats will be available o the “I vesto s” sectio of the Pulmo x website at https://i vesto s.pulmo x.com/.
Pulmo x Co po atio (Nasdaq: LUNG) is a global leade i mi imally i vasive t eatme ts fo ch o ic obst uctive pulmo a y disease (COPD). Pulmo x’s Zephy ® E dob o chial Valve, Cha tis® Pulmo a y Assessme t System, Lu gT aX® Platfo m, a d St atX® Lu g A alysis Repo ts a e desig ed to assess a d t eat patie ts with seve e emphysema/COPD who despite medical ma ageme t a e still p ofou dly symptomatic. Pulmo x eceived U.S. Food a d D ug Admi ist atio (FDA) P ema ket App oval (PMA) to comme cialize the Zephy ® E dob o chial Valve followi g its desig atio as a “b eakth ough device.” The Zephy Valve is comme cially available i mo e tha 25 cou t ies, is i cluded i global t eatme t guideli es a d is widely co side ed a sta da d of ca e t eatme t optio fo imp ovi g b eathi g, activity a d quality of life i patie ts with seve e emphysema. Fo mo e i fo matio o the Zephy Valves a d the compa y, please visit www.Pulmo x.com. Pulmo x®, Ae iSeal®, Cha tis®, Lu gT aX®, St atX®, a d Zephy ® a e egiste ed t adema ks of Pulmo x Co po atio .
